



Theme	Poster no.	Presenter name	Poster Title	Gallery
Autoinflammatory diseases	1	Stefanus Gunawan Kandinata	Witwhdrawal of Immunosuppressive Therapy in Lupus Nephritis, Is it possible?: A Systematic Review	A
	2	Rophelle Jan Salinas	Spontaneous Splenic Rupture as a Rare and Fatal Complication in a 31-year-old Female Diagnosed with Necrotizing Histiocytic Lymphadenitis (Kikuchi-Fujimoto Disease)	A
Basic science related to rheumatic diseases	3	Quang Dang Minh	Hepatocyte Growth Factor as a Potential Target for Overcoming Treatment Refractoriness in Rheumatoid Arthritis	A
Medical technologies and innovation (including AI)	4	Phonpen Akarawatcharangura Goo	Artificial intelligence assistance in screening Systemic Erythematosis Lupus in primary care setting	A
	5	Tatiana Dubinina	Identification of ankylosing spondylitis clinical manifestations in electronic health records using machine learning methods and artificial intelligence algorithms	A
	6	Kristof Filipanits	Innovative Rheumatology Teaching at the University of Pécs Medical School: Recipient of the EULAR Best Undergraduate Teaching Concept Award	A
	7	Gerber Gomez	Analytical and workflow evaluation of a fully-automated multiplexed microarray-immunoassay for the detection of eleven CTD-autoantibodies in a Malaysian reference laboratory	A
	8	Misako Higashida-Konishi	Digital biomarkers from wearables for disease activity and C-reactive protein in rheumatoid arthritis using machine learning: a multi-center prospective study	A
	9	Yuhei Ito	Serum KL-6 for Detecting Interstitial Lung Disease in Connective Tissue Diseases and Its Association with AI-Analyzed Imaging Features	A
	10	Eun Young Lee	Development and Validation of Modified BASMI: An AI Pose Estimation-based Mobile Application to Measure Spinal Mobility in Axial Spondyloarthritis	A
	11	Arinditia Putri	Evaluating Role of DXA in Hemodialysis Patients : Do We Really Need Bone Turnover Markers for Predicting Bone Mineral Density?	A
Metabolic bone diseases/ osteoporosis	12	Harsha Wechalekar	Handgrip Strength, BMI, Age and Arthritis status as predictors of Bone Mineral Density: A Cross-Sectional Analysis of T-Scores in adults.	A
Paediatric rheumatology	13	Ekaterina Alekseeva	IL-6 as a predictor of response to olokizumab in polyarticular-course juvenile idiopathic arthritis: results of the phase 2 clinical trial	A
	14	Ekaterina Alekseeva	The crucial role of emapalumab in the treatment of SJIA-associated macrophage activation syndrome: Monocentric data in Russian Federation	A
	15	Fatimah Alkhars	Belimumab for Refractory Pediatric Discoid Lupus Erythematosis: A Case Series	A
	16	Ka Nam Au	Case series of paediatric CNO presenting with fever with unknown origin diagnosed by early utilisation of PET-CT	A
	17	Reima Bakry	Cardiac valvular involvement in childhood-onset systemic lupus erythematosis: a case series and a concise review of the literature	A
	18	Reima Bakry	Childhood Cogan’s Syndrome: Clinical manifestations, treatment, and outcome A multicenter study among PReS members	A
	19	Hannah Bazer	A Diagnostic Challenge: Polyarteritis Nodosa in a Filipino Child	A
	20	Hannah Bazer	RARE BUBBLE: A Case Of Bullous Systemic Lupus Erythematosis In a Filipino Adolescent who Responded to Prednisone and Clobetasol Ointment	A
	21	Vaibhav Bellary	Progressive Pseudo-Rheumatoid Dysplasia: A Genetic Twist to a Juvenile Idiopathic Arthritis Mimic	A
	22	Christine Bernal	Clinical Features and Outcome of Patients with Juvenile Spondyloarthritis in a Tertiary Hospital in the Philippines	A
	23	Mary Jane Carbonell	Immune Thrombocytopenic Purpura as the Initial Presentation of Pediatric Systemic Lupus Erythematosis: A Case Series	A
	24	Mary Jane Carbonell	Limited Under the Skin: A Case of Pediatric Cutaneous Polyarteritis Nodosa	A
	25	Ma Theresa Collante	The Joint Project: A community-based, barangay health worker-led screening program for childhood musculoskeletal disorders in San Pedro, Laguna, Philippines	A
	26	Katherine Crawley	Long-term outcomes in Juvenile Idiopathic Arthritis: Retrospective analysis of up to 40 years of follow up at an Australian centre.	A
	27	Juan Du	Study on the Pathogenesis of JDM Based on Mendelian Randomization and Transcriptome Analysis: The Role of the IL-13 Signaling Pathway	A
	28	Ned Denebe Faner	Diagnosis and Management of Lupus Myocarditis in an Adolescent Male: A Case Report	A
	29	Zhihao Fang	Tocilizumab vs. Cyclosporine with High-Dose Glucocorticoids for sJIA-Associated MAS: A Multicenter RCT	A
	30	Ria Ghosh	Kawasaki disease with giant coronary aneurysms: Our experience at a tertiary care hospital in Eastern India	A
	31	Shounak Ghosh	Evaluation of a Rheumatology Transition Clinic: Outcomes of a multi-ethnic cohort from a single centre in the UK	A
	32	Abhishek Gollarahalli Patel	Juvenile Systemic Sclerosis: Trends in Clinical Features, Laboratory Findings, and Outcomes from a Single Center	A
	33	Adrienne Katrin Guiang-valerio	Systemic Lupus Erythematosis with Acute Motor Axonal Neuropathy Variant of Guillain-Barre Syndrome in a Pediatric Patient	A
	34	Yuko Hayashi	Clinical Characteristics of Childhood-Onset SLE and Validation of the 2019 ACR/EULAR Classification Criteria for SLE in Japanese patients	A
	35	Assunta Ho	CJADAS, patient and parent global assessment(PGA) during treatment escalation in a group of Hong Kong JIA patients including ERA	A
	36	Junjie Huang	Comparative efficacy and safety analysis of Adalimumab originator versus biosimilar in Enthesitis-Related Arthritis: An Asian experience	A
	37	Natsumi Inoue	A case of pediatric systemic sclerosis complicated by interstitial lung disease successfully treated with tocilizumab monotherapy	A





Theme	Poster no.	Presenter name	Poster Title	Gallery
Paediatric rheumatology	38	Jayathri Sandalekha Jagoda	Lupus anticoagulant-hypoprrthrombinemia syndrome as the initial presentation in a Systemic Lupus Erythematosus debut boy: a case report	A
	39	Pavneet Kaur	Giant Coronaries in Children with Kawasaki Disease: A Case Series	A
	40	Nicholas Khoo	mRNA Vaccination Does Not Perturb the Juvenile Idiopathic Arthritis Immunome Nonspecifically and Withholding Methotrexate Enhances Vaccine-Specific T-Cell Response.	A
	41	Kwang Nam Kim	Two Cases of Childhood Cartilage Disease Mistaken for Juvenile Idiopathic Arthritis	A
	42	Michael Kostik	The ethnic-related features of juvenile idiopathic arthritis in Sakha patients	A
	43	Michael Kostik	The single-center experience of tocilizumab in systemic juvenile idiopathic arthritis	A
	44	Michael Kostik	The specific features of patients with juvenile idiopathic arthritis-associated uveitis, who required eye surgery.	A
	45	Ivan Kriulin	Genetic characteristics of macrophage activation syndrome in children with rheumatic diseases: one center experience	A
	46	Ivan Kriulin	Long-term follow-up of the efficacy and safety of golimumab in patients with juvenile idiopathic arthritis	A
	47	Ivan Kriulin	Real clinical practice: long-term efficacy and safety of secukinumab in children with various types of juvenile idiopathic arthritis	A
	48	Chi Le	Clinical and paraclinical characteristics of juvenile dermatomyositis at the Vietnam National Children's Hospital 2010–2022	A
	49	Sooyoung Lee	Kawasaki disease shock syndrome in Korean children	A
	50	Reighner Manuel	Timely diagnosis and collaborative care in pediatric linear scleroderma	A
	51	Sayan Mukherjee	Differential growth pattern in Enthesitis related arthritis (ERA) versus non-ERA subtypes of Juvenile idiopathic arthritis	A
	52	Raja Natarajan	Rosai Dorfman disease – bone lesions as the first manifestation mimicking juvenile arthritis in a 15-year-old girl	A
	53	Raja Natarajan	Anti U1 RNP antibody positive neonatal lupus with absent anti-Ro /SSA and anti La/ SSB antibodies	A
	54	Irina Nikishina	Abatacept as a therapeutic option for the juvenile idiopathic inflammatory myopathies: An experience of single center	A
	55	Irina Nikishina	Clinical and laboratory characteristics of patients with juvenile-onset systemic lupus erythematosus across age groups: retrospective cohort study	A
	56	Irina Nikishina	Fibrodysplasia ossificans progressiva as a kind of axial spondyloarthritis with monogenic origin	A
	57	Irina Nikishina	Portrait of a patient with refractory systemic juvenile idiopathic arthritis based on a single-center retrospective study	A
	58	Irina Nikishina	Progressive pseudorheumatoid dysplasia: is this disease the responsibility of a rheumatologist	A
	59	Irina Nikishina	Selective IgA deficiency in rheumatic diseases with juvenile onset: single center cohort study	A
	60	Irina Nikishina	Single center experience of the calcinosis treatment with Biologics and JAK-inhibitors in children with Juvenile Idiopathic Inflammatory Myopathies	A
	61	Irina Nikishina	The use of the BCD020 rituximab bioanalog in rheumatic diseases in children: retrospective single center study	A
	62	Irina Nikishina	Transition readiness in adolescents with rheumatic disease: Results of a single-center pilot study	A
	63	Irina Nikishina	Uveitis «de novo» in patients with juvenile idiopathic arthritis under biological therapy: 20 years single center experience	A
	64	Jitendra Oswal	Chronic Recurrent Multifocal Osteomyelitis: Case series from Western India	A
	65	Jitendra Oswal	Nailfold video capillaroscopic findings in healthy Indian children	A
	66	Jitendra Oswal	Paediatric rheumatological emergencies: A critical alert for Paediatrician	A
	67	Jitendra Oswal	Pre and post treatment changes in Nailfold Video Capillaroscopy in Juvenile Dermatomyositis	A
	68	Rakesh Kumar Pilania	COVID-19 Pandemic-Driven Decline and Post-Pandemic Surge in Kawasaki Disease Incidence in Chandigarh, India (1994–2024): Evidence Supporting an Infectious Trigger	A
	69	Liudmila Shornikova	Childhood-onset Primary Sjögren's Syndrome: Clinical Characteristics and Diagnostic Opportunities	A
	70	Kai Liang Teh	Chasing Childhood Lupus Low Disease Activity (cLLDAS): Who Gets There Faster?	A
	71	Kai Liang Teh	Flare or Farewell? Predictors of a Monophasic Course in Childhood Systemic Lupus Erythematosus	A
	72	Jeter, Chi-teng Tseng	Cartilage thickness changes accessed by ultrasound among children with juvenile idiopathic arthritis: A single center experience	A
	73	Hiroyuki Wakiguchi	Ideal form of continuing professional development support organization: the Team of Middle-standing Pediatric Rheumatologists Alliance (TeMPRA) in Japan	A
	74	Kenpen Weng	Plasma S100A12 contributes to Kawasaki disease prediction and promotes the adhesion between neutrophil and endothelial cells2	A
	75	Chao-Yi Wu	Clonal Hematopoiesis of Indeterminate Potential in Childhood-Onset Systemic Lupus Erythematosus	A
	76	Joo Guan Yeo	Enhancing Childhood-Onset SLE (cSLE) Diagnosis with an Immunological-Based Machine-Learning Model	A
	77	Napapas Yothakol	Silent Gut, Dangerous Turn: Intestinal Pseudo-Obstruction in Kawasaki Disease with Early Macrophage Activation Syndrome	A





Theme	Poster no.	Presenter name	Poster Title	Gallery
Rheumatoid arthritis bDMARDs	78	Ekaterina Bogdanova	Evaluation of radiological progression in patients with rheumatoid arthritis treated with a direct interleukin 6 inhibitor olokizumab	A
	79	Shereen Ch'ng	Clinical and serological differences between responders and non-responders to biologic/targeted-synthetic DMARDs in rheumatoid arthritis: Data from the BITORA study	A
	80	Sang Wan Chung	Tumor Necrosis Factor (TNF) inhibitors does not accelerate the progression of RA-ILD : results from the KORAIL cohort	A
	81	Takayuki Fujii	Change in mental status in rheumatoid arthritis after achieving treatment targets with TNF-targeted and non-TNF-targeted therapies: a prospective cohort study	A
	82	Yuhei Fujisawa	Efficacy of biologics and JAK Inhibitors in rheumatoid arthritis patients based on the neutrophil-to-lymphocyte ratio: The ANSWER Cohort study	A
	83	Shoichi Fukui	Clinical characteristics and cytokine/chemokine profiles in rheumatoid arthritis patients who failed Boolean remission solely due to elevated patient global assessment	A
	84	Kazusato Hara	Baseline Neutrophil-to-Lymphocyte Ratio as a Predictor of SDAI Remission in RA Patients Treated with b/tsDMARDs	A
	85	Larisa Ivanova	Steroid-sparing effect of levilimab in rheumatoid arthritis in real clinical practice	A
	86	Andrei Karateev	Impact of Olokizumab on Patient-Reported Outcomes in Rheumatoid Arthritis: A Meta-Analysis	A
	87	Kou Katayama	Evaluation of the Efficacy of Ozoralizumab in High-Risk Joint Destruction Cases in Japanese Rheumatoid Arthritis Patients	A
	88	Kou Katayama	Investigation of Biologic-Free Cases in Sarilumab Treatment	A
	89	Maxim Korolev	Impact of Comorbidity Burden on the Efficacy of IL-6 Inhibitor Olokizumab in Real Clinical Practice	A
	90	Michael Kostik	Efficacy and safety of tocilizumab biosimilar versus reference tocilizumab: results of 24-week randomized double-blind study in Russia	A
	91	Satoshi Kubo	Transition in remission rates for rheumatoid arthritis patients during EULAR Recommendation Phase II	A
	92	Kuolung Lai	Evaluation of Effectiveness of Tocilizumab by Ultrasonography and Magnetic Resonance Imaging in Biologic-Naïve and First Biologic Failure Rheumatoid Arthritis Patients	A
	93	Alexander Lila	Predictors of ineffective therapy in patients with rheumatoid arthritis requiring bDMARDs/iJAK switching	A
	94	Tatiana Lisitsyna	Impact of Olokizumab and Psychopharmacotherapy on SDAI Treatment Response and Remission Rates in Rheumatoid Arthritis Patients with Depression	A
	95	Tatiana Lisitsyna	Impact of Olokizumab on Depression and Sleep Disorder Severity in Rheumatoid Arthritis Patients	A
	96	Tatiana Lisitsyna	The efficacy of olokizumab in reducing the frequency and severity of depression and fatigue in patients with rheumatoid arthritis	A
	97	Li Liu	Infection risks associated with monotherapy and combination therapies using b/tsDMARDs in rheumatoid arthritis: A systematic review and network meta-analysis	A
	98	Galina Lukina	Clinical and radiological effects of rituximab depending on smoking status in patients with rheumatoid arthritis	A
	99	Galina Lukina	Efficacy and safety of the IL-6 inhibitor Levilimab in patients with RA depending on age in real clinical practice	A
	100	Galina Lukina	The severity of inhibition of radiographic progression depending on the dosage regimen of rituximab.	A
	101	Satsuki Matsunaga	Pregnancy and childbirth Outcomes in WoCBA (Women of Childbearing Age) rheumatoid arthritis patients with high disease activity-FIRST registry	B
	102	Yusuke Miyazaki	Efficacy and Safety of Certolizumab Pegol and IL-6 Inhibitors Across Rheumatoid Factor Quartiles in Rheumatoid Arthritis: FIRST Registry	B
Rheumatoid arthritis clinical aspects and co-morbidity	103	Sei Muraoka	Therapeutic efficacy and peripheral immune cell proportions early after methotrexate and biological treatment for rheumatoid arthritis	B
	104	Kazuma Nishisaka	Anti-SS-A Antibodies Increase the Risk of Discontinuation of bDMARDs in Patients with Rheumatoid Arthritis: The ANSWER Cohort Study	B
	105	Akira Onishi	Heterogeneous treatment effects of biological DMARD versus JAK inhibitor on disease activity in patients with rheumatoid arthritis	B
	106	Josef Smolen	Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (OLE Phase III RCT Results)	B
	107	Talib Tahir	Persistence, effectiveness and treatment patterns of Upadacitinib in >2600 Australian rheumatoid arthritis patients: a retrospective analysis from the OPAL dataset	B
	108	Talib Tahir	Upadacitinib, TNFi and other JAKi in Australian rheumatoid arthritis patients: descriptive comparison of persistence and effectiveness using the OPAL dataset	B
	109	Yoshiya Tanaka	Key results from PROFILE-J - Part 2: Assessment of safety and patient reported outcomes in sarilumab-treated patients with rheumatoid arthritis	B
	110	Galymzhan Asylbekovich Togizbayev	24-Week Observational Study on Efficacy and Safety of Olokizumab in Asian Population	B
	111	Yasuhiko Yoshinaga	A 20-year study on the effects of biologics on the standardized incidence ratio of tuberculosis in RA patients by NinJa	B
	112	Alena Zagrebneva	IL-6 inhibitors in rheumatoid arthritis (RA) treatment: results from Moscow RA registry	B
	113	Bogdan Batko	Pharmacological Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review	B



Theme	Poster no.	Presenter name	Poster Title	Gallery
Rheumatoid arthritis clinical aspects and co-morbidity	114	Jung Gon Kim	The Impact of Smoking Pack-Years on Treatment Outcomes in Rheumatoid Arthritis Patients Using Tocilizumab, Abatacept, or Janus Kinase Inhibitors	B
Rheumatoid arthritis csDMARDs	115	Muhammad Arshad	Patient Reported Reasons regarding Poor Compliance to Immunosuppressives(DMARDS) in Rheumatoid Arthritis. Does it really matter?	B
Rheumatoid arthritis tsDMARDs	116	Maryam Ahmed	Effectiveness and baseline predictive factors of response to Tofacitinib in patients of Rheumatoid Arthritis in Fauji Foundation Hospital Rawalpindi	B
	117	Mustafa Alhayali	Infection Risk After Tofacitinib Withdrawal: A Comparison of 1-Day vs. 3-Day Preoperative Intervals in Joint Arthroplasty in Iraqi Patients	B
	118	Saira Elaine Anwer Khan	The potential evolution of Janus-kinase inhibitor (JAKi) use in rheumatic and musculoskeletal diseases: regional results from an international Delphi study	B
	119	Maria Borisova	Results of 12 months observation of patients with rheumatoid arthritis treated by upadacitinib.	B
	120	Almerveldy Azaria Dohong	Efficacy and Safety of Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis	B
	121	Takao Fujii	24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore)	B
	122	Shunichi Fujita	Switching to Non-TNF Biologic DMARDs in Elderly Patients with Rheumatoid Arthritis Achieving Low Disease Activity with JAK Inhibitors	B
	123	Junya Hasegawa	Predictors of Glucocorticoid Dose Reduction and Discontinuation After Initiating JAK Inhibitors in Patients with Rheumatoid Arthritis	B
	124	Kei Ikeda	Evaluation of persistence and effectiveness of baricitinib and IL-6R inhibitors in patients with rheumatoid arthritis: sub-group analysis from RA-BE-REAL	B
	125	Sivakami Janahiraman	Pharmacogenomic Approach to Identifying Genes Linked to Tofacitinib Treatment Response in Rheumatoid Arthritis	B
	126	WunLong Jheng	GWAS Identifies SNPs Associated with Treatment Response to Janus Kinase Inhibitors in Rheumatoid Arthritis in the Taiwanese population	B
	127	Kou Katayama	Examination of Clinical Outcomes by Treatment Duration of Biologics and JAK inhibitors in Nonagenarian Rheumatoid Arthritis Patients	B
	128	Kou Katayama	Is Filgotinib helpful for rheumatoid arthritis patients with high disease activity complicated with minimal or subclinical infectious lesions?	B
	129	Bo Young Kim	Machine learning-based prediction of treatment response to Janus kinase inhibitors in patients with rheumatoid arthritis	B
	130	Galina Lukina	Efficacy and safety of 13-valent anti-pneumococcal vaccine in patients with Rheumatoid arthritis	B
	131	Hong Ki Min	Comparison between JAK inhibitors and biologic disease-modifying antirheumatic drugs of pain reduction in rheumatoid arthritis: data from a KOBIO registry	C
	132	Runa Minami	Real-world use of JAK inhibitors in elderly patients with rheumatoid arthritis	C
	133	Andrew Ostor	Real-World Achievement of Treatment Targets and Maintenance of Response with Upadacitinib: Final 2-Year Outcomes from the UPHOLD Study	C
	134	Andrew Ostor	Real-World Effectiveness of Upadacitinib in Australian Patients with Rheumatoid Arthritis: A 24-Month subgroup analysis from the Observational UPHOLD Study	C
	135	Thipsukhon Sathapanasiri	Gastrointestinal perforation as a safety concern among patients with rheumatoid arthritis on Janus kinase inhibitor therapy: A network meta-analysis	C
	136	Irene Tan	Comparing the Long-Term Mortality and Cardiovascular Outcomes of Hydroxychloroquine versus Methotrexate on in Rheumatoid arthritis: A Retrospective Cohort Study	C
	137	Yoshiya Tanaka	Long-Term Safety of Upadacitinib Across Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis Encompassing ~17,000 Patient-Years of Clinical Trial Data	C
	138	Kenya Terabe	Evaluating the Effectiveness of JAK Inhibitors in Late-Onset RA	C
	139	Kai Chun Wang	Long-term Effectiveness and Drug Survival of JAK Inhibitors in Rheumatoid Arthritis: A 13-Year Single-Center Study Comparing First-Line and Non-First-Line Users	C
	140	Kazuhiro Yokota	JAK Inhibitors Suppress Osteoclast Formation and Structural Joint Damage in Patients with Rheumatoid Arthritis	C
	141	Tsuneyasu Yoshida	Perioperative outcomes of Janus kinase inhibitor use in patients with rheumatoid arthritis undergoing orthopedic surgery: A multicenter cohort study	C
Scleroderma, myositis and related syndromes	142	Oliver Distler	Patients With Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually	C
Spondylarthropathies clinical aspects and co-morbidity	143	Hema Murugesan	A rare association of Fanconi syndrome and ankylosing spondylitis	C
Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, co-morbidities and complications	144	Nureen Abdul Aziz	A Hospital-based Study on Lupus Myocarditis: Initial Presentation and Long-term Outcomes.	C
	145	Khalid Abulaban	Exploring depressive symptoms as a mediator of change in fatigue in individuals with childhood-onset lupus	C
	146	Nizaah Glaire Aggabao	Clinical Profile of Systemic Lupus Erythematosus in Adult Filipino Males: A Case Series from Cagayan Valley, Philippines	C
	147	Maria Kristene Alba	Double trouble: A case of a 30-year-old female with hyperthyroidism who presented with acute heart failure secondary to lupus myocarditis	C





Theme	Poster no.	Presenter name	Poster Title	Gallery
Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, co-morbidities and complications	148	Fatima Alduraibi	Profile of Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Single-Center Experience from a Tertiary Hospital in Saudi Arabia	C
	149	Anna Liza Alforte	Bullous systemic lupus erythematosus with concurrent lupus nephritis in a 49 -year old filipina: a case report	C
	150	Khalid A. Alnaqbi	Consensus-based Recommendations for the Referral, Diagnosis, Monitoring, and Follow-up of Systemic Lupus Erythematosus: A Delphi Study in the Gulf Region	C
	151	Amira Elina Amirul Iskandar	Early-onset versus late-onset Malaysian SLE patients: similarities and differences in clinical characteristics, haematological involvement, disease activity status and treatment	C
	152	Alekhya Amudalapalli	Clinical characteristics of disease flare in systemic lupus erythematosus	C
	153	Miyabi Ando	Effectiveness of rituximab for the treatment of SLE with refractory lupus cystitis: Two case reports	C
	154	Shekhar Angirekula	Demyelinating myelopathy and peripheral neuropathy in SLE with Sjögren’s overlap – A rare but devastating manifestation.	C
	155	Shekhar Angirekula	The Double- edged sword: High dose steroid therapy in a life threatening SLE flare causing RCVS, bradycardia and pancreatitis.	C
	156	Yoshiyuki Arinuma	Anti-Smith Antibody Stimulation to Human Primary Endothelial Cells Directly Up-regulates MMP-2 Leading to Claudin-5 Degradation	C
	157	Umbreen Arshad	Long term Outcomes and Spectrum of Organ Damage in Systemic Lupus Erythematosus: ACF lupus Cohort, Lahore, Pakistan	C
	158	Vaishnavi Arunpriyandan	Hearts under Siege: A Case Series of SLE Diagnosed Through Cardiac Manifestations	C
	159	Bea Eunice Aspiras	Systemic lupus erythematosus and antiphospholipid antibody syndrome presenting as cardiac tamponade in a young adult female: A rare case report	C
	160	Awalia Awalia	Comparison of Morbidity and Mortality in Lupus Nephritis vs. Non-Lupus Nephritis Patients – A Retrospective Analysis	C
	161	Norwin Philip Bation	Clinicopathologic Correlations in Lupus Nephritis – A Single Center Study	C
	162	Norwin Philip Bation	Recurrent Nephrotic Syndrome with Lupus Podocytopathy in Systemic Lupus Erythematosus: A Case Report	C
	163	Norwin Philip Bation	Relative Prevalence and Risk Factors for Extra-pulmonary Tuberculosis in Filipino Patients with Systemic Lupus Erythematosus	D
	164	Kyarra Bautista	Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI) in a Philippine Tertiary Hospital Setting	D
	165	Jeanaine Pearl Beltran	Thrombotic Antiphospholipid Syndrome Secondary to Systemic Lupus Erythematosus Presenting as Inferior Vena Cava and Renal Vein Thrombosis: A Diagnostic Dilemma	D
	166	Riju Bhattacharjee	Pediatric Lupus Myocarditis: Clinical Features and Outcomes from a Prospective Single-Center Study	D
	167	Maira Bizhanova	Assessment of health-related quality of life in patients with systemic lupus erythematosus in Kazakhstan	D
	168	Patrick Brzoska	Hospitalization Trends and Regional Disparities in Systemic Lupus Erythematosus in Germany	D
	169	Xiaoyan Cai	Aberrant phenotypes of circulating γδ-Tcells may be involved in the onset of systemic lupus erythematosus	D
	170	Maria Llaine Callanta	The “SMILE Filipino Patients” Project: A Dietary and Genetic Perspective on Systemic Lupus Erythematosus in Filipino Patients	D
	171	Rudrarpan Chatterjee	Anti-interferon antibodies in SLE and their association with infections in an Indian inception cohort of SLE.	D
	172	Hsin-hua Chen	Gender Differences of Outcomes in Systemic Lupus Erythematosus From 2010 to 2024: A Multi-Center Propensity Score Matched Cohort Study	D
	173	Hsin-hua Chen	Sex and other factors associated with all-cause mortality in belimumab-treated patients with systemic lupus erythematosus	D
	174	Hung Yi Chen	Genome-Wide Association Study Identifies Novel Genetic Variants in Taiwanese Patients with Systemic Lupus Erythematosus and Lupus Nephritis	D
	175	Yen Ju Chen	External Validation of a Taiwan-Specific Polygenic Risk Score for Systemic Lupus Erythematosus in a Nationwide Population	D
	176	Peter Paolo Daleon	Association of clinical parameters with histopathologic activity and chronicity indices in lupus nephritis patients	D
	177	Peter Paolo Daleon	Variables Affecting Histopathologic Change in Repeat Kidney Biopsies of Lupus Nephritis Patients	D
	178	Gantira Danasasmita	Overlap Antisynthetase Syndrome in Well Established Sjogren’s Syndrome, a Rare Combination or Unpredicted Coincidence : a Case Report	D
	179	Gantira Danasasmita	The late blooming of rhupus syndrome, overlapping nephritis lupus manifestation in long standing rheumatoid arthritis	D
	180	Juhi Dixit	Awareness regarding contraceptive measures, drug usage and factors affecting pregnancy among patients with Auto-immunne Rheumatic Diseases	D
	181	Almerveldy Azaria Dohong	The Invisible Battle: Systemic Lupus Erythematosus and the Hidden Dangers of Air Pollution – A Systematic Review and Meta-Analysis	D
	182	Tiara Ella Sari	Newly Diagnosed Severe Paediatric SLE with Bullous Systemic Lupus Erythematosus: Two Cases with Distinct Systemic Involvement	D
	183	Minette Emmanuel	Recurrent massive pleural effusion as initial manifestation of systemic lupus erythematosus	D
	184	Maimoona Firdus	Comparison of efficacy of mycophenolate mofetil and cyclophosphamide as induction therapy in lupus nephritis at one year	D



Theme	Poster no.	Presenter name	Poster Title	Gallery
Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, co-morbidities and complications	185	Ma. Therese Corazon Galolo	Mononeuritis Multiplex in Systemic Lupus Erythematosus: A Filipino Case Series on Peripheral Nerve Involvement	D
	186	Inna Gaydukova	Systemic lupus erythematosus and comorbid conditions in women with hyperuricemia	D
	187	Feiping Ge	Real-World Study on the Efficacy of Telitacicept in Systemic Lupus Erythematosus Patients with Epstein-Barr Virus (EBV) Infection	D
	188	Shounak Ghosh	Improvement in quality of life (QoL) outcomes in Lupus: a prospective survey from a patient support group in India	D
	189	Nidhi Goel	Clinical, serological and treatment profile of male SLE patients: A 5 year retrospective study from India	D
	190	Nidhi Goel	When lupus bites: Unmasking the bullous face of SLE	D
	191	Ranjan Gupta	Development and Performance of Patient Knowledge Questionnaire in Assessing Patients' Knowledge and Impact of Information Course in Systemic Lupus Erythematosus	D
	192	Ranjan Gupta	Macrophage Activation Syndrome in Systemic Lupus Erythematosus: Retrospective Study by the SLE Special Interest Group of Indian Rheumatology Association	D
	193	Chagalakonduru Guru Vijay	The Lupus Trifecta: ACR, NLR, and PLR in Predicting the Storm	D
	194	Yasuhiro Hasegawa	Practice of Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus Using Belimumab	D
	195	Allerma Herdiman	Unraveling the Uncommon: A Rare Case of SLE and Dermatomyositis Overlap Syndrome	D
	196	Alberta Hoi	Understanding the relationship between disease variables and impact of self-efficacy in SLE patients	D
	197	Jhicel Ibanez	Systemic lupus erythematosus presenting as cardiac tamponade and posterior reversible encephalopathy syndrome	D
	198	Mitsuyo Inoue	Explore of predictors to fatigue in patients with systemic lupus erythematosus	D
	199	Porntip Intapiboon	Predicting Disease Flare in SLE Patients in low disease activity state (LLDAS): The Prognostic Value of LLDAS Duration and Interleukin-6	D
	200	Radhika Satish Jakhotia	Contraceptive Use in Women with Lupus: A Cross-Sectional Study	D
	201	Bibek K C	Study of agreement between Line Immunoassay and Enzyme Linked Immunosorbent Assay for detection of Anti-dsDNA Antibodies	E
	202	Yoshiro Kanayama	Evaluation of IRF5 Nuclear Translocation Rate in B cells as a Biomarker of Disease Activity and Flares in SLE	E
	203	Wanruchada Katchamart	Effectiveness of Trimethoprim-Sulfamethoxazole Prophylaxis in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Glucocorticoids and/or Immunosuppressants: Systematic Review and Metanalysis	E
	204	Taqdees Khaliq	A Concomitant Myriad Of Neurological Symptoms In A Patient With Systemic Lupus Erythematosus	E
	205	Zumrad Khamroeva	Acute Myocardial Infarction in a Young Patient with Undiagnosed Systemic Lupus Erythematosus: A Case Report	E
	206	Minji Kim	Evaluating Urinary Acetylated Proteins as Biomarkers for Lupus Nephritis: A Prospective Cohort Study	E
	207	Mishima Koji	Association Between Low-dose Glucocorticoids (≤5 mg/day PSL) and Visual Analogue Scale in Systemic Lupus Erythematosus	E
	208	Toshihiko Komai	Urinary immune cell analysis as a non-invasive biomarker for lupus nephritis	E
	209	Sai Yasaswini Kommaraju	Immunogenicity, safety and adverse events of sequential vaccination (PCV10 and PPSV23) compared to PPSV23 alone in Systemic Lupus Erythematosus	E
	210	Michihito Kono	Prognostic factors in connective tissue disease-associated thrombotic microangiopathy	E
	211	Pande Ketut Kurniari	The Role of Immune Aging in Early Atherosclerosis in Systemic Lupus Erythematosus Patients at Ngoerah General Hospital Denpasar, Bali	E
	212	Masataka Kuwana	Incidence of Serious Infections and Herpes Zoster in Japanese Patients with Systemic Lupus Erythematosus: A Health Insurance Claims Database Study	E
	213	Mark Lawrence Lagac	Seizing the Unseen, Central Nervous System(CNS) Vasculitis in a 29-year Old Female with Systemic Lupus Erythematosus (SLE)	E
	214	TaiJu Lee	Rituximab associated with a decreased risk of lupus nephritis flare in systemic lupus erythematosus patients	E
	215	Iana Leineman	Connections between changes in adrenal function and symptoms during glucocorticoid reduction in patients with systemic lupus erythematosus	E
	216	Piem Jie Leong	Regional Variations in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Insights from Sabah, Malaysia, and the Global Perspective	E
	217	Ting Li	CRP-to-Prealbumin Ratio: A Novel Diagnostic Biomarker for Differentiating Infection versus Disease Flare in Febrile Systemic Lupus Erythematosus Patients	E
	218	Claryssa Gabrielle Ligon-Latayan	Necrotizing Enterocolitis: A diagnostic dilemma between Outcome of Methotrexate Therapy and Late-onset Systemic Lupus Erythematosus. A Case Report	E
	219	Alexander Lila	Serum calprotectin levels in Systemic Lupus Erythematosus	E
	220	Worawit Louthrenoo	Clinical features and treatment response among late-onset vs. early-onset systemic lupus erythematosus: A large multi-national prospective study	E
	221	Worawit Louthrenoo	Reproductive health knowledge and contraceptive use in never pregnant systemic lupus erythematosus patients: A cross-sectional survey	E





Theme	Poster no.	Presenter name	Poster Title	Gallery
Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, co-morbidities and complications	222	Shi Nan Luong	Health related quality of life in systemic lupus erythematosus during pregnancy	E
	223	Mahabaleshwar Mamadapur	A cross-sectional study of evaluating sexual dysfunction in females with systemic lupus erythematosus	E
	224	Mary Mirasol Manayon	Complicated Pregnancy in a Patient with Systemic Lupus Erythematosus and Thrombotic Antiphospholipid Antibody Syndrome: A Case Report	E
	225	Ida Ayu Ratih Wulansari Manuaba	The Role of Deoxyribonuclease 1, Neutrophil Extracellular Traps, and Soluble Tumor Necrosis Factor Receptor1 in the Pathogenesis of Lupus Nephritis	E
	226	Takeru Maruyama	Renal Pathological Changes in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy	E
	227	Sephora Matilos	Risk Factors for Acute Kidney Injury in Lupus Nephritis: A Single Center Study	E
	228	Kazuki Matsukawa	Successful CD19 CAR-T Therapy for Treatment-Resistant DLBCL in a Patient with Coexisting SLE: A Case Report	E
	229	Jessica Margaux Mercado	Heightened tuberculosis risk in lupus: Mycophenolate mofetil as a double-edged sword	E
	230	Ryan James Miguel	Acute diarrhea and Ileus as initial presentation of Gastrointestinal manifestation of Systemic Lupus Erythematosus in a 21-year-old Female.	E
	231	Khilola Mirakhmedova	Clinical diagnosis of systemic lupus erythematosus: Cases in Uzbekistan and global experience	E
	232	Yusuke Miyazaki	Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus and the Impact of Belimumab: LOOPS registry.	E
	233	Kamonwan Mulalin	Severe Raynaud's phenomenon led to digital amputation in a patient with systemic lupus erythematosus.	E
	234	Kavya N P	Clinical Presentation and Outcomes of Lupus Myocarditis – 20 year Retrospective Observational Study from a Tertiary Care Centre in India	E
	235	Shiori Nakagawa	Early renal remission is associated with increased likelihood of subsequent remission in lupus nephritis: a single-centre observational study in Australia	E
	236	Takehiro Nakai	Impact of organ damage on pregnancy Outcomes, and progression of organ damage during pregnancy in pregnant with systemic lupus erythematosus	E
	237	Takehiro Nakai	Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era	E
	238	Fathima Nujha Nasim	Characterizing Unusual Presentations of Recently Diagnosed Sri Lankan SLE patients: A Pilot Study to identify Disease Phenotypes and Ethno-demographic Influences.	E
	239	Hoang Thanh Van Nguyen	Lupus Enteritis Responsive to Corticosteroid Therapy: A Case Report	E
	240	Trang Nguyen Thi Ha	Factors influencing bone densities in patients with lupus nephritis at the single center of allergology and clinical immunology	E
	241	Irina Nikishina	Morphological evaluation of biopsies of minor salivary glands in patients with Sjogren's disease and healthy controls in Russia	E
	242	Fatimah Zanirah Nordin	Unravelling the Link: A Case Series of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus	E
	243	Naoya Oka	Validation of serum complements and calprotectin as biomarkers for severity of intestinal dilation in patients with Lupus Enteritis	E
	244	Rattapol Pakchotanon	Clinical characteristics and prognostic outcomes in systemic lupus erythematosus overlap syndrome	E
	245	Rattapol Pakchotanon	Comparative impact of SLE-DAS and SLEDAI-2K definitions of remission and low disease activity on quality of life in SLE	E
	246	Faisal Parlindungan	Registry-Based Study on Systemic Lupus Erythematosus in Indonesia:Disease Burden, Major Adverse Events and Treatment Trends at a National Referral Hospital	E
	247	Tatiana Popkova	Are there any links between galectins-1,3,9 and disease activity or irreversible organ damage in patients with systemic lupus erythematosus?	E
	248	Tatiana Popkova	Clinical manifestations of systemic lupus erythematosus in a Russian cohort	E
	249	Tatiana Popkova	Clinical significance of type I interferon status in patients with Systemic lupus erythematosus in Russian cohort	E
	250	Tatiana Popkova	Disease severity at onset in a Russian cohort of patients with Systemic lupus erythematosus	E
	251	Tatiana Popkova	Early marker of cardiovascular risk in systemic lupus erythematosus	E
	252	Tatiana Popkova	Quality of life in patients with systemic lupus erythematosus physical, psychoemotional components.	E
	253	Putu Novindra Pradipta	Various Rare Ocular Clinical Manifestations in Systemic Lupus Erythematosus Patients: A Case Series	E
	254	Kausalyaa Radha	Lupus Enteritis: A uncommon presentation in the conundrum of lupus.	E
	255	Leela Raman	Acquired Gitelman Syndrome in a Systemic Lupus Erythematosus: The Unusual Suspect	E
	256	Sham Santhanam	Remission and Low Disease Activity in an Indian Cohort of Lupus Patients: A Multi-Centre Retrospective Observational Study	E
	257	Prayush Sharma	Clinicodemographic Profile and Renal Outcomes in Lupus Nephritis- A Prospective Single-Center Study	E
	258	Bahareh Shateri Amiri	Evaluation of Genes and Molecular Pathways Common between Diffuse Large B-cell Lymphoma and SLE: A Systems Biology Approach	E
	259	Haili Shen	The Role of Abnormal Immune Indicators in Adverse Pregnancy Outcomes Among Women: A Single-Center Observational Study	E





Theme	Poster no.	Presenter name	Poster Title	Gallery
Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, co-morbidities and complications	260	Liudmila Shornikova	Characterization of Hematological Malignancies in Patients with Childhood-onset Primary Sjögren's Syndrome	E
	261	Pratibha Singh	Derivation of a new composite score using urinary biomarkers for the prediction of active lupus nephritis among SLE patients	E
	262	Elaine Tan	Clinical and Immunologic Profile of Patients with Overlap Syndrome Admitted in Two Tertiary Philippine Hospitals: A Cross-Sectional Study	E
	263	Michael Tan	Multicentric Castleman Disease in Systemic Lupus Erythematosus: A Rare Case Report	E
	264	Tze Chin Tan	Comorbidities, immunosuppressive therapy and the first infection-related hospitalisation in Systemic Lupus Erythematosus patients: A Retrospective Cohort Study	E
	265	Iyan Tarigan	Case series of interstitial lung disease in systemic lupus erythematosus patients	E
	266	Woon Shen Teo	Prevalence and clinical associations of cerebral atrophy in patients with systemic lupus erythematosus (SLE)	E
	267	Agnes Theodora	Right Heart Failure Secondary to Pulmonary Hypertension in SLE-Associated ILD: A Rare Case Presentation	E
	268	Wanwaleeya Tongthong	Survival Rate and Associated Factors in Systemic Lupus Erythematosus: A 12 -Year Retrospective Cohort Study	E
	269	Eishi Uechi	How Long Should New Organ Involvement Be Considered in the Clinical Course of SLE? Findings from a Japanese Cohort Study	E
	270	Naeem Ullah	Anemia in a pregnant SLE patient; Unmasking beta Thalassemia minor	E
	271	Naeem Ullah	Systemic Lupus Erythematosus presenting with Acute Sensory-Motor Polyneuropathy in an Adolescent Female; A Rare Manifestation	E
	272	Sarthak Verma	Pragmatic Outcomes of IVIG usage in Connective Tissues Diseases: A Retrospective Cohort	E
	273	Maha Chakri Willheljulya	Tjalma Syndrome (Pseudo-pseudo Meigs Syndrome): Rare Case Series	E
	274	Ka Tong Wong	Atypical Pulmonary Manifestations in Adolescent SLE: A Case Report	E
	275	Takato Yabuno	A case of SLE with various symptoms including pancreatitis after Graves' disease.	E
	276	Kohei Yo	Clinical Indicators of Long-term Renal Prognosis in Lupus Nephritis: A Single-Center Retrospective Study	E
	277	Kimberly Yu	Clinical and Socio-Economic Burden of Systemic Lupus Erythematosus In The Developed and Developing World – A Comparative Analyses	E
Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies	278	Kimberly Yu	Management Burden of Lupus Nephritis In The Developed and Developing World – A Comparative Analyses	E
	279	Wai Wai Lwin Zaw	Vitamin D Levels and The Disease Activities of Myanmar SLE patients: A Retrospective Patient Record Review Study	E
Paediatric rheumatology	280	Alam Zeb	Demographic Features and Common Clinical Presentation of SLE Patients in Northern Pakistan	E
	281	Stefanus Gunawan Kandinata	Hydroxychloroquine as a Protective Factor Against Osteoporosis in Patients with SLE	E
	282	Ekaterina Alekseeva	MRP8/14 serum levels as a predictor of stopping anti-TNF treatment in non-systemic juvenile idiopathic arthritis	E